Medivir Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Medivir wird ein Gewinn- und Umsatzwachstum von 43.1% bzw. 66.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 38.9% pro Jahr wachsen soll.

Wichtige Informationen

43.1%

Wachstumsrate der Gewinne

38.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.1%
Wachstumsrate der Einnahmen	66.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OM:MVIR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5	-193	-168	-123	4
12/31/2025	53	-158	-171	-38	4
12/31/2024	29	-94	-31	-78	4
9/30/2024	7	-117	-99	-99	N/A
6/30/2024	7	-106	-87	-87	N/A
3/31/2024	8	-97	-79	-79	N/A
12/31/2023	8	-89	-60	-60	N/A
9/30/2023	6	-87	-80	-80	N/A
6/30/2023	6	-78	-79	-78	N/A
3/31/2023	4	-75	-78	-78	N/A
12/31/2022	4	-89	-102	-102	N/A
9/30/2022	23	-95	-83	-83	N/A
6/30/2022	23	-94	-83	-83	N/A
3/31/2022	23	-88	-87	-87	N/A
12/31/2021	32	-63	-49	-49	N/A
9/30/2021	3	-50	-47	-44	N/A
6/30/2021	19	-32	-44	-41	N/A
3/31/2021	23	-27	-46	-43	N/A
12/31/2020	20	-43	-61	-58	N/A
9/30/2020	30	-64	-81	-80	N/A
6/30/2020	14	-91	-98	-96	N/A
3/31/2020	14	-91	-110	-109	N/A
12/31/2019	9	-123	-150	-148	N/A
9/30/2019	21	-206	-196	-196	N/A
6/30/2019	23	-254	-244	-241	N/A
3/31/2019	21	-333	-293	-288	N/A
12/31/2018	24	-350	-325	-319	N/A
9/30/2018	15	-339	-345	-337	N/A
6/30/2018	17	-348	N/A	-322	N/A
3/31/2018	23	-348	N/A	-322	N/A
12/31/2017	37	-360	N/A	-358	N/A
9/30/2017	42	-379	N/A	-341	N/A
6/30/2017	63	-353	N/A	-315	N/A
3/31/2017	90	-320	N/A	-270	N/A
12/31/2016	93	-295	N/A	-182	N/A
9/30/2016	-16	-262	N/A	-108	N/A
6/30/2016	70	-218	N/A	4	N/A
3/31/2016	279	-95	N/A	106	N/A
12/31/2015	474	32	N/A	347	N/A
9/30/2015	950	268	N/A	855	N/A
6/30/2015	1,456	652	N/A	1,253	N/A
3/31/2015	1,775	916	N/A	1,277	N/A
12/31/2014	1,767	1,133	N/A	1,014	N/A
9/30/2014	1,537	1,005	N/A	580	N/A
6/30/2014	1,000	620	N/A	101	N/A
3/31/2014	476	229	N/A	4	N/A
12/31/2013	446	16	N/A	43	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MVIRDie Einnahmen des Unternehmens (66.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (0.05% pro Jahr).

Hohe Wachstumseinnahmen: MVIRDie Einnahmen des Unternehmens (66.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MVIR in 3 Jahren voraussichtlich hoch sein wird

Medivir Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 45%

Consensus revenue estimates increase by 21%

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Price target decreased by 16% to kr23.39

Consensus revenue estimates fall by 78%

Recent updates

Medivir AB Announces Finalisation of the Phase 1B/2A Study of fostroxacitabine bralpamide

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

New minor risk - Share price stability

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

New major risk - Financial position

Consensus EPS estimates fall by 45%

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Consensus revenue estimates increase by 21%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Price target decreased by 16% to kr23.39

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 78%

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Consensus revenue estimates increase by 47%, EPS downgraded

Independent Chairman of the Board recently bought kr374k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Chief Executive Officer recently bought kr209k worth of stock

Price target increased by 14% to kr28.08

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to kr27.96

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research